-Advertisement-
-Advertisement-
FDA Alerts
Hematology
Trending Topics
FDA Grants Orphan Drug Designation to AFM13 for the Treatment of T-cell Lymphoma
Posted on
The U.S. Food and Drug Administration has granted orphan drug designation to AFM13 for the treatment of patients with T-cell lymphoma, according to a press release. The designation includes peripheral T cell lymphoma (pTCL), a subtype of T-cell lymphoma.
AFM13 is currently being investigated in a Phase 2 registration-directed study.
Read the full press release here.
Source: Affimed
-Advertisement-
-Advertisement-
![](https://medjournal360.com/wp-content/uploads/2022/08/medjournal_white_Hematology.png)
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved